Shares of Illumina, Inc. (ILMN, Financial) outperformed during the second quarter. Illumina is the leading provider of next generation DNA sequencing instruments and consumables. In April, the company reported strong first quarter results. Revenues increased 21%, ahead of Wall Street estimates, driven by strength across the entire product portfolio. Earnings also exceeded expectations. We think Illumina's strong first quarter results were driven in part by market share gains, which may have accelerated after the company's main competitor announced it was evaluating strategic alternatives. (Neal Kaufman)
From Ron Baron’s second quarter 2013 commentary.
From Ron Baron’s second quarter 2013 commentary.
